Tools
Which door should you try first?
Every price on this site is a cash price, and for most people a cash price is the wrong number. Coverage, the federal platform and a non-obesity indication can all beat the compounded field. This routes you to the cheapest door that applies to you — including when that door is not us.
Why the order matters
A $50 Medicare copay is below the cheapest compounded program in this entire database, where the floor is $169 a month all-in for tirzepatide. Commercial coverage frequently beats it too. Roughly $350 through the federal platform buys an FDA-approved product for less than the upper half of the compounded field charges for an unapproved one.
Compounded cash-pay is the route for people none of the others serve. That is still a great many people — but fewer than it was six months ago, and a comparison site that does not say so is selling you something.
If cash-pay compounded is your route
Start with the true cost calculator at the dose you expect to settle at, then read the pharmacy verification guide — in the absence of FDA pre-market review, who makes the medicine is most of what you have.
Questions
What is the cheapest way to get a GLP-1?
In rough order: Medicare's GLP-1 Bridge if you are eligible (maximum $50 monthly copay), then commercial insurance coverage, then a non-obesity indication route such as sleep apnea or MASH, then roughly $350 a month through the federal TrumpRx platform, and only then cash-pay compounded.
Should I use insurance or pay cash for a GLP-1?
Establish coverage first. A copay under a covered benefit is usually far below any cash price, and every figure on this site is a cash price for people without a coverage route.
Can I get coverage without an obesity diagnosis?
Sometimes. Zepbound has been approved for obstructive sleep apnea since December 2024, and noncirrhotic MASH is eligible for Part D coverage.